JP2580076B2 - 粘膜組織へ医薬品を投与するための装置 - Google Patents

粘膜組織へ医薬品を投与するための装置

Info

Publication number: JP2580076B2
Authority: JP; Japan
Prior art keywords: drug; patient; transmucosal delivery; base; chamber
Prior art date: 1989-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2512701A

Other languages

English (en)

Japanese (ja)

Other versions

JPH05500176A (ja

Inventor

スタンレー，セオドア・エイチ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Utah

Original Assignee

University of Utah

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-05

Filing date

1990-08-03

Publication date

1997-02-12

1990-08-03 Application filed by University of Utah filed Critical University of Utah

1993-01-21 Publication of JPH05500176A publication Critical patent/JPH05500176A/ja

1997-02-12 Application granted granted Critical

1997-02-12 Publication of JP2580076B2 publication Critical patent/JP2580076B2/ja

2012-02-12 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 336
210000004400 mucous membrane Anatomy 0.000 title claims abstract description 41
229940079593 drug Drugs 0.000 claims abstract description 271
238000000034 method Methods 0.000 claims abstract description 38
230000000694 effects Effects 0.000 claims abstract description 30
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 62
210000004877 mucosa Anatomy 0.000 claims description 34
102000004877 Insulin Human genes 0.000 claims description 31
108090001061 Insulin Proteins 0.000 claims description 31
239000003937 drug carrier Substances 0.000 claims description 31
229940125396 insulin Drugs 0.000 claims description 31
210000000214 mouth Anatomy 0.000 claims description 25
239000000463 material Substances 0.000 claims description 9
210000003169 central nervous system Anatomy 0.000 claims description 8
239000000017 hydrogel Substances 0.000 claims description 8
210000005166 vasculature Anatomy 0.000 claims description 8
230000005540 biological transmission Effects 0.000 claims description 6
230000035699 permeability Effects 0.000 claims description 5
239000000556 agonist Substances 0.000 claims description 4
239000003961 penetration enhancing agent Substances 0.000 claims description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 2
229960002428 fentanyl Drugs 0.000 claims description 2
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
210000002345 respiratory system Anatomy 0.000 claims description 2
230000002686 anti-diuretic effect Effects 0.000 claims 1
230000003474 anti-emetic effect Effects 0.000 claims 1
230000002460 anti-migrenic effect Effects 0.000 claims 1
229940124630 bronchodilator Drugs 0.000 claims 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims 1
229960004943 ergotamine Drugs 0.000 claims 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims 1
210000003238 esophagus Anatomy 0.000 claims 1
230000032696 parturition Effects 0.000 claims 1
210000003800 pharynx Anatomy 0.000 claims 1
229920001184 polypeptide Polymers 0.000 claims 1
230000001737 promoting effect Effects 0.000 claims 1
239000008247 solid mixture Substances 0.000 claims 1
239000003623 enhancer Substances 0.000 abstract description 33
238000002347 injection Methods 0.000 abstract description 17
239000007924 injection Substances 0.000 abstract description 17
229940124597 therapeutic agent Drugs 0.000 abstract description 8
210000005178 buccal mucosa Anatomy 0.000 abstract description 7
229940126585 therapeutic drug Drugs 0.000 abstract description 2
239000008280 blood Substances 0.000 description 25
210000004369 blood Anatomy 0.000 description 25
210000004027 cell Anatomy 0.000 description 23
239000000243 solution Substances 0.000 description 22
238000001647 drug administration Methods 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 18
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
239000008103 glucose Substances 0.000 description 17
238000009792 diffusion process Methods 0.000 description 13
235000009508 confectionery Nutrition 0.000 description 11
210000004185 liver Anatomy 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 7
239000003833 bile salt Substances 0.000 description 7
229940039009 isoproterenol Drugs 0.000 description 7
239000007788 liquid Substances 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
239000012528 membrane Substances 0.000 description 6
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 6
239000002904 solvent Substances 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
230000006870 function Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
208000019901 Anxiety disease Diseases 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
230000036506 anxiety Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229940093761 bile salts Drugs 0.000 description 4
210000002200 mouth mucosa Anatomy 0.000 description 4
230000001473 noxious effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
235000019333 sodium laurylsulphate Nutrition 0.000 description 4
230000009747 swallowing Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000004087 circulation Effects 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
210000002249 digestive system Anatomy 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000004677 mucosal permeability Effects 0.000 description 3
239000006187 pill Substances 0.000 description 3
-1 polyethylene Polymers 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
206010057362 Underdose Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000004519 grease Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000035515 penetration Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000002985 plastic film Substances 0.000 description 2
229920006255 plastic film Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
ZEFOXNBIQIPHOP-UHFFFAOYSA-N 2,3-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC=CC(O)=C1C(C)C ZEFOXNBIQIPHOP-UHFFFAOYSA-N 0.000 description 1
OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
102400000748 Beta-endorphin Human genes 0.000 description 1
101800005049 Beta-endorphin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960001391 alfentanil Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000009118 appropriate response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000004566 building material Substances 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 1
229950004689 carfentanil Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
229940009979 dehydrocholate Drugs 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960000394 droperidol Drugs 0.000 description 1
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000002359 drug metabolite Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
229960001690 etomidate Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002456 hexobarbital Drugs 0.000 description 1
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
DGABKXLVXPYZII-SIBKNCMHSA-M hyodeoxycholate Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-M 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
229950010274 lofentanil Drugs 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
150000004667 medium chain fatty acids Chemical class 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
229950006124 oxazolam Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
230000036280 sedation Effects 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical group C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Chemical class 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
229960002178 thiamazole Drugs 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
229940054870 urso Drugs 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nutrition Science (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Physiology (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Media Introduction/Drainage Providing Device (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Saccharide Compounds (AREA)
Vending Machines For Individual Products (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Plant Substances (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

JP2512701A 1989-09-05 1990-08-03 粘膜組織へ医薬品を投与するための装置 Expired - Fee Related JP2580076B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/403,743 US5122127A (en)	1985-05-01	1989-09-05	Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US403,743		1989-09-05

Publications (2)

Publication Number	Publication Date
JPH05500176A JPH05500176A (ja)	1993-01-21
JP2580076B2 true JP2580076B2 (ja)	1997-02-12

Family

ID=23596847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2512701A Expired - Fee Related JP2580076B2 (ja)	1989-09-05	1990-08-03	粘膜組織へ医薬品を投与するための装置

Country Status (11)

Country	Link
US (1)	US5122127A (de)
EP (1)	EP0491778B1 (de)
JP (1)	JP2580076B2 (de)
AT (1)	ATE149362T1 (de)
AU (1)	AU643233B2 (de)
CA (1)	CA2066425C (de)
DE (1)	DE69030095T2 (de)
DK (1)	DK0491778T3 (de)
ES (1)	ES2097760T3 (de)
NO (1)	NO920856L (de)
WO (1)	WO1991003271A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2678514B1 (fr) *	1991-07-05	1993-11-05	Fred Cabrera	Dispositif pour l'absorption dermique de solutes medicamenteux.
IT1250691B (it) *	1991-07-22	1995-04-21	Giancarlo Santus	Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
CH686816A5 (de) *	1992-02-04	1996-07-15	Asulab Ag	Einrichtung zur Abgabe eines Arzneimittels.
GB9212511D0 (en) *	1992-06-12	1992-07-22	Cortecs Ltd	Pharmaceutical compositions
FI941336A7 (fi) *	1993-03-23	1994-09-24	Diomedes Oy	Annostelulaitteena toimiva laastari
AU6957594A (en) *	1993-05-26	1994-12-20	Becton Dickinson & Company	Patch, with system and apparatus for manufacture
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
GB9409281D0 (en)	1994-05-10	1994-06-29	Svedman Paul	Transdermal device
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
EP0806940B1 (de)	1994-12-22	2003-04-09	AstraZeneca AB	Aerosol-arzneiformulierungen
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
CA2206657C (en)	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
US5762494A (en) *	1997-03-24	1998-06-09	Archambault; Gregory A.	Applicator device and method
GB9717770D0 (en) *	1997-08-21	1997-10-29	Scherer Ltd R P	Pharmaceutical composition
US7153845B2 (en) *	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US8765177B2 (en) *	1997-09-12	2014-07-01	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US5981552A (en) *	1998-10-23	1999-11-09	Taylor Pharmaceuticals	Sublingual and buccal compositions of droperidol and method for treating migraine
US6103257A (en) *	1998-07-17	2000-08-15	Num-Pop, Inc.	System for delivering pharmaceuticals to the buccal mucosa
US6358060B2 (en)	1998-09-03	2002-03-19	Jsr Llc	Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en)	1998-09-03	2002-02-05	Jsr Llc	Medicated chewing gum delivery system for nicotine
US6242473B1 (en)	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6270781B1 (en)	1999-01-08	2001-08-07	Maxim Pharmaceuticals, Inc.	Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
WO2000074616A1 (en) *	1999-06-02	2000-12-14	Tano Robert S	Multipurpose first-aid bandage
WO2001005352A1 (en) *	1999-07-19	2001-01-25	Andrew John Ashworth	Apparatus and method for administration of medication
AU7520200A (en) *	1999-09-18	2001-04-24	Heinz-Dieter Unger	Container for receiving a pharmaceutical agent which acts upon or via the skin
WO2001089476A1 (en) *	2000-05-19	2001-11-29	Npd Llc	Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
JP4898073B2 (ja) *	2000-07-31	2012-03-14	ニュコメデダンマルクアンパーツセルスカブ	鼻内投与用フェンタニル組成物
US20020106407A1 (en) *	2000-12-11	2002-08-08	Dennis Coleman	Method and apparatus for treating breakthrough pain
EP1386251A4 (de) *	2001-03-02	2005-11-23	Euro Celtique Sa	Verfahren und gerät zur verdichtung von individualisierten dosierformen
US7438701B2 (en) *	2001-07-26	2008-10-21	Durect Corporation	Local concentration management system
RU2004107501A (ru) *	2001-08-14	2005-02-20	Байотай Терапис Корпорейшн (Fi)	Способ лечения алкоголизма или злоупотребления алкоголем
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005501602A (ja) *	2001-08-29	2005-01-20	カルバーリョ、リカルドエイ．ピー．デ	治療薬を組織に一方向送達するための封鎖可能な移殖型装置
CA2461661A1 (en) *	2001-10-19	2003-05-01	Maxim Pharmaceuticals, Inc.	Use of histamine to treat liver disease
CA2466083A1 (en) *	2001-11-06	2003-05-15	Maxim Pharmaceuticals, Inc.	Compositions for the treatment of infectious diseases
AU2003295857A1 (en) *	2002-11-21	2004-06-18	Ada Technologies, Inc.	Strobe desorption method for high boiling point materials
US7833802B2 (en) *	2002-11-21	2010-11-16	Ada Technologies, Inc.	Stroboscopic liberation and methods of use
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
US7416546B2 (en)	2003-05-05	2008-08-26	Boston Scientific Scimed, Inc.	Tissue patches and related delivery systems and methods
US8034048B2 (en) *	2003-05-05	2011-10-11	Boston Scientific Scimed, Inc.	Tissue patches and related delivery systems and methods
US7470266B2 (en) *	2003-09-16	2008-12-30	I-Flow Corporation	Fluid medication delivery device
FR2863174B1 (fr) *	2003-12-08	2006-11-24	Galderma Res & Dev	Dispositif de dosage d'un produit destine a etre applique sur la peau
WO2005060960A2 (en) *	2003-12-11	2005-07-07	Maxim Pharmaceuticals, Inc.	Use of histamine to treat bone disease
AT500095B8 (de) *	2004-01-23	2007-02-15	Braun Werner Mag	Transdermales abgabesystem
US8492106B2 (en)	2004-05-24	2013-07-23	Universitat Zu Koln	Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
GB2414675B (en) *	2004-06-05	2006-09-06	Dewan Fazlul Hoque Chowdhury	Transdermal drug delivery device
WO2006009975A2 (en) *	2004-06-22	2006-01-26	Maxim Pharmaceuticals, Inc.	Histamine to treat disorders affecting muscle function
US8377711B2 (en) *	2005-04-04	2013-02-19	Ada Technologies, Inc.	Stroboscopic liberation and methods of use
BRPI0616843A2 (pt) *	2005-10-05	2011-07-05	Acu Rate Pty Ltd	dispositivo de controle de fluxo, e, componente para um conjunto intravenoso
US8202535B2 (en)	2006-01-06	2012-06-19	Acelrx Pharmaceuticals, Inc.	Small-volume oral transmucosal dosage forms
US8357114B2 (en) *	2006-01-06	2013-01-22	Acelrx Pharmaceuticals, Inc.	Drug dispensing device with flexible push rod
US8753308B2 (en)	2006-01-06	2014-06-17	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en)	2006-01-06	2013-09-17	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) *	2006-01-06	2016-03-22	Acelrx Pharmaceuticals, Inc.	Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) *	2006-01-06	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en)	2006-01-06	2014-10-21	Acelrx Pharmaceuticals, Inc.	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) *	2007-01-05	2015-06-30	Aceirx Pharmaceuticals, Inc.	Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en)	2007-01-05	2012-08-28	Acelrx Pharmaceuticals, Inc.	Bioadhesive drug formulations for oral transmucosal delivery
US8642016B2 (en)	2006-07-21	2014-02-04	Jsrnti, Llc	Medicinal delivery system, and related methods
US20080085331A1 (en) *	2006-10-06	2008-04-10	Gluskin Anna E	Composition and method for raising blood glucose level
US8363215B2 (en)	2007-01-25	2013-01-29	Ada Technologies, Inc.	Methods for employing stroboscopic signal amplification and surface enhanced raman spectroscopy for enhanced trace chemical detection
US7817274B2 (en) *	2007-10-05	2010-10-19	Jingyun Zhang	Compact spectrometer
WO2009070459A1 (en)	2007-11-30	2009-06-04	Jingyun Zhang	Miniature spectrometers working with cellular phones and other portable electronic devices
US8945592B2 (en)	2008-11-21	2015-02-03	Acelrx Pharmaceuticals, Inc.	Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
GB2467377A (en)	2009-02-02	2010-08-04	Nemaura Pharma Ltd	Transdermal patch with extensor means actuated to expel drug towards the skin of a patient
JP2012526840A (ja) *	2009-05-13	2012-11-01	プロテインデリヴァリーソリューションズエルエルシー	膜貫通送達のための製剤系
US8690841B2 (en) *	2009-07-09	2014-04-08	R. Gary Diaz	Wound care system
BR112012012945A2 (pt)	2009-11-25	2020-12-29	Arisgen Sa	Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
EP2526971A1 (de)	2011-05-25	2012-11-28	ArisGen SA	Mukosale Freisetzung von Arzneimitteln
BR112017013311B1 (pt)	2014-12-23	2022-05-31	Acelrx Pharmaceuticals, Inc	Aparelho para a dispensação de formas de dosagem via oral e transmucosal
CN106546533B (zh)	2015-09-20	2019-12-10	大连世佩达光谱智能检测科技有限公司	一种用全孔径角抛物镜收集表面增强拉曼散射光谱的设备
EP4183385A1 (de) *	2021-11-23	2023-05-24	ETH Zurich	Schleimhautsaugpflaster und verwendung davon zur arzneimittelabgabe
EP4417243A1 (de) *	2023-02-15	2024-08-21	Heraeus Medical GmbH	Implantat zur verzögerten wirkstofffreisetzung

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US109677A (en) *		1870-11-29		Improvement in confectionery for druggists
US802190A (en) *	1903-03-20	1905-10-17	Solomon E Heineman	Emergency-bandage for surgical purposes.
US747525A (en) *	1903-08-22	1903-12-22	Belle Rector Willis	Surgical apparatus.
US1430642A (en) *	1921-01-29	1922-10-03	Phillip E Gross	Artificial fishing bait
US1593858A (en) *	1923-02-12	1926-07-27	Robert W Venable	Confection
US1602344A (en) *	1924-01-09	1926-10-05	Eagle Peter	Medicating compress
US1971560A (en) *	1928-10-22	1934-08-28	Parker Meyer Dennis Company	Candy and holder therefor
US1847415A (en) *	1929-12-31	1932-03-01	Silver S Snell	Holder for candy suckers
US1915614A (en) *	1930-12-22	1933-06-27	Parker Charles	Solidified edible and method of making same
DE577563C (de) *	1932-07-31	1933-06-01	Hugo Kratz Dr	Vorrichtung zum Auftragen von Fluessigkeiten
US2096611A (en) *	1935-02-07	1937-10-19	Parker Meyer Dennis Company	Confection
US2208120A (en) *	1938-03-02	1940-07-16	William B Coleman	Pharmaceutical preparation and method of making same
US2246778A (en) *	1939-12-21	1941-06-24	Edward E Cahoon	Safety handle for confections
US2295042A (en) *	1941-08-25	1942-09-08	Robert L Llewellyn	Fish plug
GB550296A (en) *	1941-11-17	1943-01-01	British Oxygen Co Ltd	Improvements in or relating to the administration of inhalant gas mixtures
US2323656A (en) *	1942-07-28	1943-07-06	Helfenstein John	Fishhook
US2508560A (en) *	1946-10-22	1950-05-23	Mozel A Adams	Fishing lure
GB628709A (en) *	1947-10-06	1949-09-02	William Edmondson	An appliance for the production and administration of gas-vapour mixtures
US2488272A (en) *	1948-08-06	1949-11-15	Harry E Davis	Cellophane stick and method of making it
US2469589A (en) *	1948-09-20	1949-05-10	Toy Pop Corp	Confection with support therefor
GB646680A (en) *	1948-10-27	1950-11-29	William Edmondson	Apparatus for mixing the vapour of a volatile anaesthetic with air
US2807262A (en) *	1952-12-10	1957-09-24	Robert B Lew	Perforated plastic adhesive tape bandage
US2915061A (en) *	1956-12-24	1959-12-01	Cyprane Ltd	Volatile anaesthetic vaporising apparatus
US2926121A (en) *	1957-03-20	1960-02-23	American Home Prod	Therapeutic candy-like product and its preparation
US2857908A (en) *	1957-04-26	1958-10-28	Leslie S Cornfield	Candy coated tongue depressor
US2897624A (en) *	1958-06-27	1959-08-04	Frederick O Yakel	Conservation fishhooks
US2963404A (en) *	1958-09-05	1960-12-06	Pfizer & Co C	Tannate candy making, and product
US3210247A (en) *	1960-04-16	1965-10-05		Anti-epileptic i-cyclohexyl-z-methyl- aiviino propane salt of phenyl ethyl barbituric acid
CH410963A (de) *	1960-07-28	1966-04-15	Hommel Ag	Verfahren zur Herstellung von 5-Allyl-5-(B-oxypropyl)-barbitursäure
GB968054A (en) *	1962-02-15	1964-08-26	Cyprane Ltd	Improvements in volatile anaesthetic vaporising apparatus
US3264115A (en) *	1962-07-10	1966-08-02	Harry E Davis	Safety lollipop
US3493652A (en) *	1962-09-14	1970-02-03	Charles W Hartman	Controlled release medicament
US3271256A (en) *	1963-03-21	1966-09-06	Richardson Merrell Inc	Chloroform in hard candy
US3172179A (en) *	1963-08-12	1965-03-09	John V Schafer	Collar fastener
GB1083896A (en) *	1964-04-30	1967-09-20	Dunster Lab Ltd	Vehicles for administering drugs
GB1071659A (en) *	1964-06-09	1967-06-07	Cyprane Ltd	Improvements in or relating to volatile anaesthetic vaporising apparatus
US3344030A (en) *	1964-06-15	1967-09-26	American Home Prod	Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
US3341414A (en) *	1964-08-27	1967-09-12	Merck & Co Inc	N-cyclohexylsulfamate solubilized medication
US3367332A (en) *	1965-08-27	1968-02-06	Gen Electric	Product and process for establishing a sterile area of skin
GB1171691A (en) *	1967-02-24	1969-11-26	Forest Laboratories	Lond-Acting Oral Carrier
US3418743A (en) *	1967-05-02	1968-12-31	Roy H. Halvorsen	Fish lure with retractable hooks
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3556811A (en) *	1969-08-11	1971-01-19	Walton J Smith	Low-fermentability hard candy
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
BE795384A (fr) *	1972-02-14	1973-08-13	Ici Ltd	Pansements
FI50578C (fi) *	1972-09-05	1976-05-10	Haemeen Anttila Yrjoe Sakari	Syöksykoukuilla varustettu uistin
US3867927A (en) *	1974-06-13	1975-02-25	Patrick F Hergott	Tongue blade sucker
US3943928A (en) *	1974-09-25	1976-03-16	Lariccia Anthony H	Eliminating the safety hazard in oral dissolution of a solid
US4093709A (en) *	1975-01-28	1978-06-06	Alza Corporation	Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) *	1975-01-28	1978-12-26	Alza Corporation	Structured orthoester and orthocarbonate drug delivery devices
US4168308A (en) *	1976-03-12	1979-09-18	Apoteksvarucentralen Vitrum Ab	Composition for enhancing the administration of pharmacologically active agents
US4060084A (en) *	1976-09-07	1977-11-29	Alza Corporation	Method and therapeutic system for providing chemotherapy transdermally
US4078568A (en) *	1976-10-12	1978-03-14	Northern Illinois Research, Inc.	Plastic composition and method
DE2712161C2 (de) *	1977-03-19	1983-01-05	Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz	Zahn- und Mundpflegemittel
DD132404B1 (de) *	1977-08-12	1983-04-27	Roland Schubert	Verfahren zur herstellung eines arzneimitteltraegers
US4139627A (en) *	1977-10-06	1979-02-13	Beecham Inc.	Anesthetic lozenges
EP0001907B1 (de) *	1977-11-07	1981-02-11	Beecham Inc.	Anästhetische Lutschtabletten und Verfahren zu ihrer Herstellung
JPS5562012A (en) *	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
FR2441341A1 (fr) *	1978-11-15	1980-06-13	Batriaud Delautre Marie	Bonbons perfores et stries a profil special
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
US4291015A (en) *	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
US4307075A (en) *	1979-09-13	1981-12-22	American Home Products Corporation	Topical treatment of aphthous stomatitis
JPS56100714A (en) *	1980-01-16	1981-08-12	Teijin Ltd	Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane
US4341208A (en) *	1980-07-14	1982-07-27	Whitman Medical Corporation	Moisture-retentive covering for ointment application
JPS5758615A (en) *	1980-09-26	1982-04-08	Nippon Soda Co Ltd	Film agnent and its preparation
JPS5843368B2 (ja) *	1980-10-30	1983-09-27	日東電工株式会社	消炎鎮痛貼付剤
US4346709A (en) *	1980-11-10	1982-08-31	Alza Corporation	Drug delivery devices comprising erodible polymer and erosion rate modifier
IL61721A (en) *	1980-12-16	1984-03-30	Blank Izhak	Nitroglycerin preparations
JPS6059207B2 (ja) *	1981-03-13	1985-12-24	日東電工株式会社	複合製剤の製法
SU1011126A1 (ru) *	1981-07-14	1983-04-15	Всесоюзный научно-исследовательский и испытательный институт медицинской техники	Средство дл лечени сахарного диабета
JPS5924964B2 (ja) *	1981-08-11	1984-06-13	帝人株式会社	徐放性製剤
US4372942A (en) *	1981-08-13	1983-02-08	Beecham Inc.	Candy base and liquid center hard candy made therefrom
CH653550A5 (de) *	1981-10-20	1986-01-15	Sandoz Ag	Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4460368A (en) *	1981-10-29	1984-07-17	Almedco, Inc.	Trans-dermal medication system
CA1208558A (en) *	1982-10-07	1986-07-29	Kazuo Kigasawa	Soft buccal
US4573996A (en) *	1984-01-03	1986-03-04	Jonergin, Inc.	Device for the administration of an active agent to the skin or mucosa
US4551329A (en) *	1984-01-20	1985-11-05	Joan Harris	Oral medicament lollipop
US4588580B2 (en) *	1984-07-23	1999-02-16	Alaz Corp	Transdermal administration of fentanyl and device therefor
JPS61101641A (ja) *	1984-10-22	1986-05-20	Fuji Heavy Ind Ltd	空燃比制御装置
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
DE3527893A1 (de) *	1985-08-03	1987-02-05	Merck Patent Gmbh	Epikutan-testpflaster
US4666441A (en) *	1985-12-17	1987-05-19	Ciba-Geigy Corporation	Multicompartmentalized transdermal patches
US4917688A (en) *	1987-01-14	1990-04-17	Nelson Research & Development Co.	Bandage for transdermal delivery of systemically-active drug
US4812305A (en) *	1987-11-09	1989-03-14	Vocal Rodolfo S	Well medicine strip
US4849224A (en) *	1987-11-12	1989-07-18	Theratech Inc.	Device for administering an active agent to the skin or mucosa

1989
- 1989-09-05 US US07/403,743 patent/US5122127A/en not_active Expired - Fee Related
1990
- 1990-08-03 EP EP90913635A patent/EP0491778B1/de not_active Expired - Lifetime
- 1990-08-03 JP JP2512701A patent/JP2580076B2/ja not_active Expired - Fee Related
- 1990-08-03 DE DE69030095T patent/DE69030095T2/de not_active Expired - Fee Related
- 1990-08-03 DK DK90913635.0T patent/DK0491778T3/da active
- 1990-08-03 WO PCT/US1990/004368 patent/WO1991003271A1/en not_active Ceased
- 1990-08-03 ES ES90913635T patent/ES2097760T3/es not_active Expired - Lifetime
- 1990-08-03 CA CA002066425A patent/CA2066425C/en not_active Expired - Fee Related
- 1990-08-03 AT AT90913635T patent/ATE149362T1/de not_active IP Right Cessation
- 1990-08-03 AU AU63539/90A patent/AU643233B2/en not_active Ceased
1992
- 1992-03-04 NO NO92920856A patent/NO920856L/no unknown

Also Published As

Publication number	Publication date
AU6353990A (en)	1991-04-08
JPH05500176A (ja)	1993-01-21
DE69030095D1 (de)	1997-04-10
EP0491778B1 (de)	1997-03-05
NO920856L (no)	1992-04-06
EP0491778A4 (en)	1992-08-12
AU643233B2 (en)	1993-11-11
DE69030095T2 (de)	1997-09-25
WO1991003271A1 (en)	1991-03-21
CA2066425A1 (en)	1991-03-06
NO920856D0 (no)	1992-03-04
CA2066425C (en)	1998-01-20
ATE149362T1 (de)	1997-03-15
EP0491778A1 (de)	1992-07-01
DK0491778T3 (da)	1997-09-08
US5122127A (en)	1992-06-16
ES2097760T3 (es)	1997-04-16

Legal Events

Date	Code	Title	Description
2003-11-07	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP2580076B2 (ja)	1997-02-12	粘膜組織へ医薬品を投与するための装置
EP0490916B1 (de)	1995-10-18	Zusammensetzungen und verfahren zur herstellung von im mund zersetzlichen heilmitteln
US5785989A (en)	1998-07-28	Compositions and methods of manufacturing of oral dissolvable medicaments
EP0200490B1 (de)	1991-03-20	Mittel zur nichtsystemischen Verabreichung von Sedativa, Analgetika und Anaesthetica
AU642664B2 (en)	1993-10-28	Transmucosal dosage form
KR101606944B1 (ko)	2016-03-28	경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
US5855908A (en)	1999-01-05	Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
WO2019005759A1 (en)	2019-01-03	APPARATUS AND METHODS FOR RAPID TRANSMUCAL DRUG DELIVERY
AU645966B2 (en)	1994-02-03	Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
US20050118241A1 (en)	2005-06-02	Platform for transdermal formulations (ptf)
AU684888B2 (en)	1998-01-08	Method and compositions for noninvasive dose to effect administration of lipophilic drugs